Estimaciones de analistas de Wall Street para ImmunityBio, Inc. (IBRX): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.08 | ||
| 2026-08-04 | $-0.22 | $-0.08 | -175.0% |
| 2026-05-07 | $-0.62 | $-0.08 | -675.0% |
| 2026-02-23 | $-0.06 | $-0.08 | +25.0% |
| 2025-11-04 | $-0.07 | $-0.10 | +30.0% |
| 2025-08-05 | $-0.10 | $-0.10 | +0.0% |
| 2025-05-12 | $-0.15 | $-0.12 | -25.0% |
| 2025-03-03 | $-0.09 | $-0.26 | +65.4% |
Ratios de valoración
| Precio / Valor contable | -8.04 |
| EV / EBITDA | -10.70 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $44000 | $45000 | $47000 | $43000 | $605000 | $934000 | $240000 | $622000 | $14.7M | $113.3M |
| Coste de Ventas | 0 | 0 | -$3.1M | $9.0M | 0 | 0 | 0 | 0 | 0 | $753000 |
| Beneficio Bruto | $44000 | $45000 | $3.2M | -$9.0M | $605000 | $934000 | $240000 | $622000 | $14.7M | $112.5M |
| I+D | $26.5M | $39.8M | $53.4M | $48.9M | $139.5M | $196.0M | $248.1M | $232.4M | $190.1M | $207.9M |
| Generales y Administrativos | $94.4M | $53.8M | $35.5M | $9.1M | $71.3M | $135.3M | $102.7M | $129.6M | $168.8M | $147.2M |
| Gastos Operativos | $120.9M | $93.6M | $88.9M | $57.9M | $221.5M | $331.2M | $351.5M | $362.9M | $358.9M | $368.6M |
| Beneficio Operativo | -$124.5M | -$99.1M | -$98.4M | -$66.9M | -$220.9M | -$330.3M | -$351.3M | -$362.2M | -$344.2M | -$256.0M |
| EBITDA | -$117.7M | -$90.7M | -$86.7M | -$56.9M | -$204.2M | -$320.8M | -$351.9M | -$478.7M | -$264.4M | -$223.6M |
| Gastos por Intereses | $66000 | $618000 | $433000 | $5.9M | $9.1M | $14.8M | $47.1M | $86.7M | $131.7M | $112.5M |
| Beneficio Antes de Impuestos | -$121.4M | -$96.9M | -$96.7M | -$65.9M | -$226.0M | -$349.8M | -$417.3M | -$583.9M | -$413.6M | -$351.6M |
| Impuestos | -$572000 | -$493000 | -$503000 | -$97000 | -$1.8M | $9000 | $34000 | -$40000 | 0 | -$135000 |
| Beneficio Neto | -$120.8M | -$96.4M | -$96.2M | -$65.8M | -$221.9M | -$346.8M | -$416.6M | -$583.2M | -$413.6M | -$351.4M |
| BPA | $-0.37 | $-0.30 | $-0.30 | $-0.42 | $-0.59 | $-0.89 | $-1.04 | $-1.15 | $-0.59 | $-0.38 |
| BPA Diluido | $-0.37 | $-0.30 | $-0.30 | $-0.42 | $-0.59 | $-0.89 | $-1.04 | $-1.15 | $-0.62 | $-0.38 |
| Acciones en Circulación (Diluidas) | $328.6M | $316.1M | $325.0M | $383.2M | $383.2M | $389.2M | $399.9M | $508.6M | $700.4M | $919.9M |
Precio
| Precio | $7.91 |
| Capitalización | $8.3B |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: AGIO · BEAM · COGT · DNLI · ETNB · GLPG · LQDA
Explorar sector: Healthcare · Biotechnology
Más secciones de IBRX: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones